Opportunity Information: Apply for RFA AG 17 059
The National Institutes of Health (NIH) funding opportunity titled "Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)" (Funding Opportunity Number RFA-AG-17-059; CFDA 93.866) supports research focused on a practical problem in dementia care: many people with Alzheimers disease and related dementias (ADRD) also live with multiple other chronic conditions, and those comorbidities can strongly influence which additional (ancillary) treatments clinicians choose and how well those treatments work. The goal of this announcement is to generate evidence that improves the effectiveness of treatment strategies for those commonly co-occurring conditions in the context of ADRD, where usual care pathways often become complicated by cognitive impairment, caregiver burden, medication interactions, and differences in how patients can adhere to or benefit from standard interventions.
The FOA encourages projects that examine or test approaches to managing comorbid conditions alongside ADRD, with an emphasis on real-world clinical decision-making rather than highly controlled, artificial research settings. Applicants may propose observational treatment studies (for example, studies that compare outcomes under different commonly used treatment strategies as they are delivered in typical care) or pragmatic clinical trials designed to work within everyday healthcare systems. In other words, the intent is not just to learn whether an intervention can work under ideal circumstances, but whether it is feasible, acceptable, and effective when implemented in the clinical environments where older adults with dementia actually receive care.
A key feature of this opportunity is its phased R21/R33 structure. The R21 phase is meant to fund pilot work that demonstrates feasibility, refines intervention or trial procedures, and meets clearly defined milestones. If those R21 milestones and transition criteria are met, the project can move into the R33 phase, which supports broader implementation of a pragmatic trial. The transition is not automatic; it is determined through an administrative review based on successful completion of the criteria established during the R21 period. This design is meant to reduce risk by ensuring that larger, more resource-intensive pragmatic trials are launched only when the preliminary work shows the approach is workable and ready to scale.
From an applicant and organizational eligibility standpoint, this is a broad, inclusive NIH grant opportunity. Eligible applicants include many types of U.S. governmental entities (state, county, city/township, and special district governments), independent school districts, and public housing authorities/Indian housing authorities. Academic eligibility covers public and state-controlled institutions of higher education as well as private institutions of higher education. The FOA also allows applications from federally recognized Native American tribal governments and other tribal organizations, along with nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), and small businesses. In addition, the announcement explicitly notes eligibility for a range of institutions and organizations often emphasized in federal outreach and capacity-building, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). This breadth reflects an interest in encouraging diverse research settings and populations, which can be especially important in ADRD where care access and comorbidity patterns vary substantially across communities.
Administratively, the opportunity is categorized as discretionary funding and uses the grant funding instrument. It is listed under the health activity category, was created on 2016-10-27, and had an original closing date of 2017-01-12. The listed award ceiling is $200,000, signaling that the initial supported work is intended to be a bounded pilot effort consistent with the R21 phase purpose, with the possibility of expansion into the R33 phase if milestones are achieved. Overall, this FOA is designed for teams interested in improving real-world treatment strategies for the multiple chronic conditions that commonly accompany ADRD, using a stepwise approach that starts with feasibility and transitions to pragmatic testing once readiness has been demonstrated.Apply for RFA AG 17 059
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2016-10-27.
- Applicants must submit their applications by 2017-01-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this NIH funding opportunity?
The opportunity is titled "Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AG-17-059.
What is the CFDA number listed for this opportunity?
The CFDA number provided is 93.866.
What is the main problem this FOA is trying to address?
This FOA focuses on a practical challenge in dementia care: many people with Alzheimers disease and related dementias (ADRD) also have multiple other chronic conditions, and those comorbidities can strongly influence which additional (ancillary) treatments clinicians choose and how well those treatments work.
What is the overall goal of the research supported by this announcement?
The goal is to generate evidence that improves the effectiveness of treatment strategies for commonly co-occurring chronic conditions in the context of ADRD, where usual care pathways can be complicated by cognitive impairment, caregiver burden, medication interactions, and differences in how patients can adhere to or benefit from standard interventions.
What kinds of studies does the FOA encourage?
The FOA encourages projects that examine or test approaches to managing comorbid conditions alongside ADRD, emphasizing real-world clinical decision-making rather than highly controlled or artificial research settings.
Does this FOA support observational treatment studies?
Yes. Applicants may propose observational treatment studies, such as studies comparing outcomes under different commonly used treatment strategies as they are delivered in typical care.
Does this FOA support pragmatic clinical trials?
Yes. The FOA supports pragmatic clinical trials designed to work within everyday healthcare systems.
What does "real-world" or "pragmatic" mean in the context of this FOA?
The intent is to learn not only whether an intervention can work under ideal circumstances, but also whether it is feasible, acceptable, and effective when implemented in the clinical environments where older adults with dementia actually receive care.
How is this funding opportunity structured (R21/R33)?
This FOA uses a phased R21/R33 structure. The R21 phase supports pilot work to demonstrate feasibility, refine procedures, and meet defined milestones. If milestones and transition criteria are met, the project may move into the R33 phase for broader implementation of a pragmatic trial.
What is the purpose of the R21 phase?
The R21 phase is intended to fund pilot work that demonstrates feasibility, refines the intervention or trial procedures, and meets clearly defined milestones.
What is the purpose of the R33 phase?
The R33 phase supports broader implementation of a pragmatic trial after readiness has been demonstrated during the R21 phase.
Is the transition from R21 to R33 automatic?
No. The transition is not automatic. It occurs only if the R21 milestones and transition criteria are successfully completed and an administrative review determines the criteria have been met.
How is the R21-to-R33 transition decision made?
The decision is made through an administrative review based on successful completion of the criteria established during the R21 period.
Why does this FOA use a phased (R21/R33) approach?
The phased design reduces risk by ensuring that larger, more resource-intensive pragmatic trials are launched only when preliminary work shows the approach is workable and ready to scale.
What types of organizations are eligible to apply?
Eligibility is broad. The FOA allows applications from many U.S. governmental entities, independent school districts, public housing authorities/Indian housing authorities, public/state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments and other tribal organizations, nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, U.S. territories or possessions, and foreign (non-U.S.) organizations.
Are U.S. state, county, city/township, or special district governments eligible?
Yes. The FOA lists eligibility for state, county, city/township, and special district governments.
Are independent school districts eligible to apply?
Yes. Independent school districts are included in the listed eligible applicants.
Are public housing authorities or Indian housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
Are higher education institutions eligible?
Yes. Public and state-controlled institutions of higher education, as well as private institutions of higher education, are eligible.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are explicitly included as eligible applicants.
Are nonprofit organizations eligible?
Yes. Both 501(c)(3) and non-501(c)(3) nonprofit organizations are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, with the note that this includes for-profit organizations other than small businesses; small businesses are also listed separately as eligible.
Are small businesses eligible?
Yes. Small businesses are included among eligible applicants.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The announcement explicitly notes that non-U.S. entities (foreign organizations) are eligible.
Does the FOA encourage participation from specific institution types that are often part of federal outreach and capacity-building efforts?
Yes. It explicitly notes eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, and faith-based or community-based organizations, among others (such as regional organizations and U.S. territories or possessions).
What is the funding instrument used for this opportunity?
The opportunity uses the grant funding instrument.
What type of funding is this categorized as?
It is categorized as discretionary funding.
What activity category is this opportunity listed under?
It is listed under the health activity category.
When was this opportunity created?
The listing notes a created date of 2016-10-27.
What was the original closing date listed for this FOA?
The original closing date shown is 2017-01-12.
What is the listed award ceiling?
The listed award ceiling is $200,000.
What does the award ceiling suggest about the scope of work?
The award ceiling signals that the initial supported work is intended to be a bounded pilot effort consistent with the purpose of the R21 phase, with the possibility of expansion into the R33 phase if milestones are achieved.
What is meant by "ancillary treatments" in this FOA?
Based on the description, ancillary treatments refer to additional treatments clinicians choose to manage the chronic conditions that commonly co-occur with ADRD, and the FOA is interested in how multimorbidity affects those choices and outcomes.
What care complexities in ADRD does this FOA highlight as relevant to treatment strategies?
The FOA highlights that usual care pathways may be complicated by cognitive impairment, caregiver burden, medication interactions, and differences in how patients can adhere to or benefit from standard interventions.
Browse more opportunities from the same category: Health
Next opportunity: Cultural Programming in the People’s Republic of China
Previous opportunity: BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 17 059
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 17 059) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (R21/R33) Apply for PAR 17 037 Funding Number: PAR 17 037 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Education: Initiative for Maximizing Student Development (IMSD) Program (R25) Apply for PAR 17 040 Funding Number: PAR 17 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Focused Technology Research and Development (R01) Apply for PAR 17 045 Funding Number: PAR 17 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Research for Technology Development (R21) Apply for PAR 17 046 Funding Number: PAR 17 046 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 140504CONT17 Funding Number: CDC RFA PS14 140504CONT17 Agency: Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Selective Cell and Network Vulnerability in Aging and Alzheimers Disease (R01) Apply for PAR 17 047 Funding Number: PAR 17 047 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimers Disease Risk (R01) Apply for RFA AG 17 061 Funding Number: RFA AG 17 061 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| USAID Child Blindness Program (CBP) Apply for PGRD 16 0004 Funding Number: PGRD 16 0004 Agency: Agency for International Development Category: Health Funding Amount: $250,000 |
| Research Career Enhancement Award to Advance Therapy Development for Alzheimer's (K18) Apply for PAR 17 052 Funding Number: PAR 17 052 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Postbaccalaureate Research Education Program (PREP) (R25) Apply for PAR 17 051 Funding Number: PAR 17 051 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Knowledge Management Center for Illuminating the Druggable Genome (U24) Apply for RFA RM 16 024 Funding Number: RFA RM 16 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Education: Initiative for Maximizing Student Development (IMSD) Program (R25) Apply for PAR 17 053 Funding Number: PAR 17 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource Dissemination and Outreach Center for Illuminating the Druggable Genome (U24) Apply for RFA RM 16 025 Funding Number: RFA RM 16 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01) Apply for RFA AI 16 081 Funding Number: RFA AI 16 081 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| Leveraging Existing Cohort Studies to Clarify Risk and Protective Factors for Alzheimers Disease and Related Dementias (R01) Apply for PAR 17 054 Funding Number: PAR 17 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Enhancing the Target and Biomarker Discovery Efforts of the AMP-AD and M2OVE-AD Consortia (R01) Apply for RFA AG 17 054 Funding Number: RFA AG 17 054 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Global Infectious Disease Research Training Program (D43) Apply for PAR 17 057 Funding Number: PAR 17 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigator Initiated Extended Clinical Trial (R01) Apply for PAR 17 056 Funding Number: PAR 17 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Planning Grant for Global Infectious Disease Research Training Program (D71) Apply for PAR 17 058 Funding Number: PAR 17 058 Agency: National Institutes of Health Category: Health Funding Amount: $46,000 |
| Pragmatic Trials for Dementia Care in Long-term Services and Support (LTSS) Settings (R01) Apply for RFA AG 17 064 Funding Number: RFA AG 17 064 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 17 059", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.